ArticleJournal of medicinal chemistry2023

Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

Mu-Chun Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.